Kawase I, Komuta K, Ogura T, Fujiwara H, Hamaoka T, Kishimoto S
Cancer Res. 1985 Apr;45(4):1663-8.
Four monoclonal antibodies to MH134 murine syngeneic hepatoma cells, 3H1, 7C2, 11G2, and 12A2, were produced by hybridomas constructed by fusing P3-X63-Ag8-U1 murine myeloma cells with spleen cells of a C3H/HeN mouse immunized with the syngeneic tumor cells. Immunodiffusion analysis with rabbit anti-mouse immunoglobulin antisera showed that 3H1, 7C2, 11G2, and 12A2 are IgG2a, IgM, IgG1, and IgG2a, respectively. Enzyme-linked immunosorbent assay using cells of five syngeneic tumor lines, MH134, MM102, MM46, MM48, and X5563, and lymph node cells of C3H/HeN and C57BL/6 mice showed that 3H1 specifically bound to MH134 tumor cells, whereas 7C2, 11G2, and 12A2 reacted not only with MH134 but also with MM102 and MM46 tumor cells. None of these monoclonal antibodies bound either to cells of MM48 or X5563 tumor lines or to normal lymph node cells. These results strongly suggest that MH134 tumor cells display at least two kinds of tumor-associated antigens on their cell surfaces: one is expressed uniquely by MH134 tumor cells, which are recognized by 3H1; the other is commonly shared by MH134, MM102, and MM46 tumor cells, which are determined by the other three antibodies. 3H1, 11G2, and 12A2 but not 7C2 were found to be able to induce antibody-dependent cellular cytotoxicity (ADCC) against MH134 tumor cells. Target specificity of ADCC induced by these monoclonal antibodies was identical with that seen in enzyme-linked immunosorbent assay. 3H1, 7C2, and 12A2 but not 11G2 exhibited complement-dependent cytotoxicity, showing the same specificity in target cell lysis as that seen in enzyme-linked immunosorbent assay or ADCC. Pretreatment of MH134 tumor cells with 7C2 inhibited ADCC of both 11G2 and 12A2. Pretreatment of the tumor cells with 11G2 inhibited complement-dependent cytotoxicity of both 7C2 and 12A2. Neither ADCC nor complement-dependent cytotoxicity of 3H1 was inhibited by the pretreatment of the cells with 7C2 or 11G2. These results strongly suggest that tumor-associated antigens recognized by 3H1 are located apart from that recognized by 7C2, 11G2, and 12A2 and that the binding sites of the latter three antibodies are closely associated with, or identical with, each other in the tumor-associated antigen. The ability of 12A2 to induce ADCC against MH134 tumor cells was significantly stronger than that of 3H1 or 11G2.(ABSTRACT TRUNCATED AT 400 WORDS)
通过将P3-X63-Ag8-U1鼠骨髓瘤细胞与用同基因肿瘤细胞免疫的C3H/HeN小鼠的脾细胞融合构建杂交瘤,产生了四种针对MH134鼠同基因肝癌细胞的单克隆抗体,即3H1、7C2、11G2和12A2。用兔抗小鼠免疫球蛋白抗血清进行免疫扩散分析表明,3H1、7C2、11G2和12A2分别为IgG2a、IgM、IgG1和IgG2a。使用五种同基因肿瘤细胞系(MH134、MM102、MM46、MM48和X5563)的细胞以及C3H/HeN和C57BL/6小鼠的淋巴结细胞进行酶联免疫吸附测定,结果显示3H1特异性结合MH134肿瘤细胞,而7C2、11G2和12A2不仅与MH134反应,还与MM102和MM46肿瘤细胞反应。这些单克隆抗体均不与MM48或X5563肿瘤细胞系的细胞或正常淋巴结细胞结合。这些结果有力地表明,MH134肿瘤细胞在其细胞表面展示至少两种肿瘤相关抗原:一种由MH134肿瘤细胞独特表达,可被3H1识别;另一种由MH134、MM102和MM46肿瘤细胞共同拥有,由其他三种抗体识别。发现3H1、11G2和12A2能够诱导针对MH134肿瘤细胞的抗体依赖性细胞毒性(ADCC),而7C2不能。这些单克隆抗体诱导的ADCC的靶标特异性与酶联免疫吸附测定中观察到的相同。3H1、7C2和12A2表现出补体依赖性细胞毒性,在靶细胞裂解中显示出与酶联免疫吸附测定或ADCC中相同的特异性。用7C2预处理MH134肿瘤细胞可抑制11G2和12A2的ADCC。用11G2预处理肿瘤细胞可抑制7C2和12A2的补体依赖性细胞毒性。用7C2或11G2预处理细胞均不抑制3H1的ADCC或补体依赖性细胞毒性。这些结果有力地表明,3H1识别的肿瘤相关抗原与7C2、11G2和12A2识别的肿瘤相关抗原位于不同位置,并且后三种抗体的结合位点在肿瘤相关抗原中彼此紧密相关或相同。12A2诱导针对MH13肿瘤细胞的ADCC的能力明显强于3H1或11G2。(摘要截短至400字)